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PURPOSE:
Oncologic surgical planning has become increasingly collaborative in recent years, as breast surgeons and plastic surgeons partner to deliver the most optimal results from both oncologic and aesthetic perspectives. Radiation therapy (XRT) is a highly effective component of breast cancer treatment algorithms; however, patients often suffer from associated pernicious side effects resulting in delayed or compromised breast reconstruction. XRT has profoundly destructive short and long-term effects on skin, soft tissue, and surrounding vasculature. Thus, there is an extraordinary need for an effective, yet safe method of radiation injury prophylaxis. Amifostine (AMF) is one of only a few FDA approved prophylactic radio-protectants, however, it has not been widely adopted in the clinical setting. One reason for this is lingering uncertainty over whether AMF potentially protects cancer cells from XRT in addition to healthy cells. While the oncologic safety of AMF in the setting of head and neck cancer is well studied, it has yet to be investigated in the setting of breast cancer. The purpose of this study was to evaluate the oncologic safety of Amifostine and determine its effect on triple negative breast cancer in the setting of XRT.
METHODS:
Two ER-/PR-/Her2-breast cancer cell lines, MDA-MB-231 and MDA-MB-468, and one healthy breast cell line, Female Fibroblasts (FF), were investigated. A standardization study was performed to identify appropriate doses of XRT and WR-1065. 25,000 MDA-MB-231 and MDA-MB-468 cells and 50,000 FF cells were seeded in 24-well plates. After 24 hours, WR-1065, the active metabolite of AMF, was added to experimental wells to achieve a final concentration of 0.25 mM. Untreated wells functioned as controls. Following a 20-minute exposure, cells were washed and media replaced. Immediately thereafter, a single dose of 0, 10, or 20 Gy XRT was administered. Live and dead cells were quantified 48 hours after XRT. Percent cell death was calculated. Two sample t-test was performed to compare values between groups and two-tail p-values were determined.
RESULTS:
Treatment with WR-1065 significantly reduced healthy FF cell death after XRT compared to untreated controls. While it does not eliminate healthy cell death, it demonstrated a significant radio-protective effect at both Both MDA-MB-468 and MDA-MB-231 cells exhibited radio-sensitivity with substantial cell death at 10 and 20 Gy. Pretreatment with WR-1065 did not demonstrate cancer cell protection. Cancer cells retained their radio-sensitivity despite prophylactic treatment with WR-1065, as pretreated cells achieved the same degree of cell death as untreated cells.
CONCLUSIONS:
Amifostine does not protect triple negative breast cancer cells from XRT. This study demonstrated its proficiency to selectively protect healthy cells from XRT, while cancer cells remained radiosensitive. These results not only support the oncologic safety of Amifostine, but also identify this drug as a highly effective prophylactic radioprotectant in the setting of breast cancer. Further investigation is now warranted to validate these findings in vivo. To improve transgender health disparities, the Department of Public Health of San Francisco County received funding to establish a gender health program for under-and uninsured transgender patients. Herein we present our hallmark experience in establishing a government funded transgender surgery program for uninsured patients in San Francisco, the first of its kind in the United States. METHODS: The Gender Health SF (GHSF) Program operates in accordance with the WPATH SOC (World Professional Association for Transgender Health Standards of Care). In addition, GHSF specifically requires referrals from a PCP who has treated the patient continuously for at least one year. A formal assessment is generated, and the patient is assigned a patient navigator (trans individuals who have undergone surgery) to assist in assembling the required documentation, and to provide support and education. When patients are deemed stable from a medical, psychological, and social standpoint, they are referred for surgical evaluation.
RESULTS:
A retrospective review of patient outcomes (via EMR, electronic medical record) and quality-improvement patient survey data was performed. Since the origin of the GHSF program in 2013, 351 surgical cases have been completed (genital surgeries and select other procedures were referred to outside providers). Feminizing mammoplasties were the modal surgery (150 cases), with 109 vaginoplasties and 59 gender affirming mastectomies as the second and third most common gender affirming procedures performed. Comprehensive facial feminization is growing most rapidly, with 12 cases in 2017, and 30 in 2018. Clinical outcomes data for a single surgeon were reviewed. This surgeon completed 93 primary feminizing mammoplasties; there were no surgical site infections, and one revision was performed to correct minor postoperative asymmetry. Of the 28 gender affirming mastectomies performed, one patient had partial nipple loss due to persistent tobacco use, and three minor scar revisions were performed on other patients. Of 183 survey respondents, 97.8% felt "very" or "completely" prepared for surgery, reflecting the effectiveness of our pre-operative screening and education/ support programs. 91.8% of respondents noted satisfaction with surgery, with 76% noting "complete/extreme" satisfaction.
CONCLUSION: Key components to success in providing transgender surgical care for uninsured patients include the requirement of a stable PCP for referrals and a Peer Navigator. Complication rates for chest and breast surgeries in this public health sample mirror those previously reported in the private population, and our preliminary satisfaction data confirms effective quality outcomes. Most remarkably, because patients referred through this program must establish stable social circumstance to qualify for surgery, we have seen an unprecedented improvement in functional societal roles as these motivated patients seek stable jobs, housing, and health maintenance. Further review is in progress to quantify the long term psychosocial benefits not only on an individual basis, but for society at large. Our program has established that public funding can effectively improve health disparities in uninsured transgender patients with notably low complications and very high patient satisfaction.
